Literature DB >> 1394189

Reversal of basic fibroblast growth factor-mediated autocrine cell transformation by aromatic anionic compounds.

M Benezra1, I Vlodavsky, A Yayon, R Bar-Shavit, J Regan, M Chang, S Ben-Sasson.   

Abstract

NIH-3T3 cells transfected with basic fibroblast growth factor (bFGF) fused to a signal peptide sequence (spbFGF cells) are transformed in vitro and tumorigenic in vivo. Treatment of spbFGF cells with low and nontoxic concentrations (0.5-2.5 micrograms/ml) of negatively charged, nonsulfated aromatic compounds (e.g., aurin tricarboxylic acid, 4-hydroxyphenoxyacetic acid) resulted in restoration of their normal proliferative rate, morphological appearance, and adhesion properties. Binding and cross-linking experiments using 125I-labeled bFGF revealed that these alterations were associated with an up-regulation of high affinity receptors bFGF receptors was induced by these compounds in spbFGF cells that were seeded on fibronectin to enforce a firm cell attachment and flattening. Thus, induction of spbFGF cell adhesion and spreading may not be related to restoration of normal bFGF-receptor interactions. Although the negatively charged aromatic compounds mimic many of the effects of heparin in other systems (e.g., release of heparin- and heparan sulfate-bound proteins, inhibition of heparanase), heparin, heparan sulfate, and dextran sulfate were not effective at the low concentrations of the anionic compounds used in the present study. Likewise, suramin, a sulfated aromatic molecule, was effective at toxic concentrations, 400-600-fold higher than the nonsulfated aromatic compounds. The development of defined, nontoxic anionic compounds may provide a new strategy to interfere with the autonomous and anchorage independent mode of cell growth involved in autocrine cell transformation and cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Authors:  E Levi; R Fridman; H Q Miao; Y S Ma; A Yayon; I Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.

Authors:  H Q Miao; D M Ornitz; E Aingorn; S A Ben-Sasson; I Vlodavsky
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 3.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  Antitumor activity of FCE 26644 a new growth-factor complexing molecule.

Authors:  F Sola; M Farao; E Pesenti; A Marsiglio; N Mongelli; M Grandi
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 5.  Heparin-Mimicking Polymers: Synthesis and Biological Applications.

Authors:  Samantha J Paluck; Thi H Nguyen; Heather D Maynard
Journal:  Biomacromolecules       Date:  2016-10-14       Impact factor: 6.988

6.  Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.

Authors:  Kazuyuki Sugahara; Kuntebommanahalli N Thimmaiah; Hemant K Bid; Peter J Houghton; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

7.  Gene expression-based screening for inhibitors of PDGFR signaling.

Authors:  Alena A Antipova; Brent R Stockwell; Todd R Golub
Journal:  Genome Biol       Date:  2008-03-01       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.